Phenotype-based Pain Guidance for Head and Neck Cancer-Related Pain (pilot)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional phase 2 pilot study will classify patients’ pain into phenotypes and provide a tailored pain management plan. Participants will be seen at baseline, day 3, and day 7 to track pain levels, side effects, and use of breakthrough medications. The study focuses on head and neck cancer pain and aims to determine if phenotype-based guidelines can safely reduce pain within the first week of treatment planning. Safety will be monitored by recording medication-related adverse effects. The trial will not include patients who have prior cancer treatments.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All adult male and female patients with HNC-related pain that have at least 5 or more intensity average pain intensity in the last one week on a 11-point numeric verbal pain rating scale (NVRS), where 0 is indicative of "no pain" and 10 is suggestive of "worst pain imaginable."
* Participants with a diagnosis of head and neck cancer-related pain.

Exclusion Criteria:

* Participants on active or history of prior oncological treatment (radiation therapy, chemotherapy, or immune check point inhibitors) will be excluded.

Where it's running

• Shukat Khanum Memorial Cancer Hospital & Research Centre
  Lahore, Punjab Province, Pakistan Recruiting

Study contacts

• Study coordinator: Khawaja S Nasir
• Email: shehryarnasir@skm.org.pk
• Phone: 924235905000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Airway ultrasound in head and neck cancer patients

  This observational study tests whether neck ultrasound measurements of the airway match CT measurements in adults with maxillofacial cancer undergoing surgery with anesthesia.

  Recruiting at 2 sites University Hospital Dubrava · Zagreb, City of Zagreb and 1 other locations · NCT07910149

• Safe use of metformin and naproxen to help prevent cancer in people with Fanconi anemia

  This study tests whether metformin and naproxen can lower the chance of cancer developing in adults with Fanconi anemia.

  Recruiting at 2 sites Phase 1 Rockefeller University · Minneapolis, Minnesota and 1 other locations · NCT07901959

• Iparomlimab and Tuvonralimab With Cetuximab Before Surgery in Resectable Oral Cancer

  In this phase 2 study, patients with locally advanced, resectable oral squamous cell carcinoma will receive a combination of iparomlimab, tuvonralimab, and cetuximab before surgery to see if the treatment is safe and can shrink tumors.

  Recruiting Phase 2 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Shanghai, Shanghai Municipality · NCT07882888

• SumMET: Targeted radioligand therapy for c-MET–positive solid tumors

  This first‑in‑human study tests the safety and potential effectiveness of a radioligand therapy called [225Ac]Ac-FL-261 in adults with advanced or metastatic solid tumors that overexpress c-MET.

  Recruiting at 2 sites Phase 1/2 Full-Life Technologies UK Limited · Minneapolis, Minnesota and 1 other locations · NCT07873450

• Using Silverlon for head and neck patients with tracheostomies

  This early-phase study tests whether Silverlon dressings can prevent severe skin reactions under tracheostomy collars in adults with head and neck cancer.

  Recruiting Phase 1 State University of New York - Upstate Medical University · Syracuse, New York · NCT07856732

• Hyperfractionated radiotherapy vs high-dose cisplatin-based chemoradiation for head and neck cancer

  This trial tests whether giving hyperfractionated radiation therapy is as effective as high-dose cisplatin with radiation for people with head and neck squamous cell carcinoma.

  Recruiting King Hussein Cancer Center · Amman · NCT07801235

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.